Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

DGAP-HV: Carl Zeiss Meditec AG: Bekanntmachung der Einberufung zur Hauptversammlung am 30.03.2022 in Jena mit dem Ziel der europaweiten Verbreitung gemäß §121 AktGhttp://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
DGAP-HV: Carl Zeiss Meditec AG: Bekanntmachung der Einberufung zur Hauptversammlung am 30.03.2022 in Jena mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
DGAP-HV: Carl Zeiss Meditec AG: Bekanntmachung der Einberufung zur Hauptversammlung am 30.03.2022 in Jena mit dem Ziel der europaweiten Verbreitung gemäß §121 AktG
Agilent Announces Cash Dividend of 21 Cents per Sharehttps://www.cyansecurity.com/:
Agilent Announces Cash Dividend of 21 Cents per Share


Agilent Technologies, Inc. (NYSE: A) today announced a quarterly dividend of 21 cents per share of common stock will be paid on April 27, 2022, to all shareholders of record as of the close of

Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiencyhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and OPKO’s Once-Weekly NGENLA™ (somatrogon) Injection Receives Marketing Authorization in European Union for Treatment of Pediatric Growth Hormone Deficiency


Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human

European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adultshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
European Medicines Agency Approves Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults


Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) has approved the company’s 20-valent pneumococcal conjugate vaccine (PCV20), which will be marketed in the European

Dexcom Announces Upcoming Virtual Conference Presentations: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Upcoming Virtual Conference Presentations


DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on the company at the following upcoming virtual investor conferences:




  • Brice Bobzien, Vice President, Finance

Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Agehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Provide Update on Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced plans to extend their rolling submission to the U.S. Food and Drug Administration (FDA) seeking to amend the Emergency Use

DGAP-News: Carl Zeiss Meditec erzielt weiteres Wachstum im ersten Quartal 2021/22http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
DGAP-News: Carl Zeiss Meditec erzielt weiteres Wachstum im ersten Quartal 2021/22
DGAP-News: Carl Zeiss Meditec erzielt weiteres Wachstum im ersten Quartal 2021/22
DGAP-News: Carl Zeiss Meditec achieves further growth in first quarter of 2021/22http://www.meditec.zeiss.com/C125679E0051C774?Open: CARL ZEISS MEDITEC AG
DGAP-News: Carl Zeiss Meditec achieves further growth in first quarter of 2021/22
DGAP-News: Carl Zeiss Meditec achieves further growth in first quarter of 2021/22
Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports Fourth Quarter and Fiscal Year 2021 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2021.



Fourth Quarter 2021 Financial Highlights:




  • Revenue grew 23%

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Pfizer’s Hospital leadership team – Angela Lukin, Global President; Annaliesa Anderson

Humana Specialty Pharmacy Expands Access to New Cancer Treatment Options: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Specialty Pharmacy Expands Access to New Cancer Treatment Options


Humana Specialty Pharmacy has announced two significant additions to its comprehensive, personalized and targeted oncology therapies.



Patients can now receive the following drugs, delivered to

Pfizer Reports Fourth-Quarter and Full-Year 2021 Resultshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Reports Fourth-Quarter and Full-Year 2021 Results


Pfizer Inc. (NYSE: PFE) reported strong financial results for fourth-quarter and full-year 2021 and provided 2022 total company financial guidance(4). In addition, Pfizer raised its previous 2022

Agilent Highlights Integrated Automation Solutions at SLAS 2022Pexels:
Agilent Highlights Integrated Automation Solutions at SLAS 2022


Agilent Technologies Inc. (NYSE: A) highlights innovative laboratory automation solutions at the SLAS2022 International Conference and Exhibition held February 5 through February 9, 2022, at the

Quidel to Hold Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 17th, 2022
Quidel to Hold Fiscal Fourth Quarter and Full Year 2021 Financial Results Conference Call on February 17th, 2022


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report fiscal fourth quarter and full year

Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDAhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and BioNTech Initiate Rolling Submission for Emergency Use Authorization of Their COVID-19 Vaccine in Children 6 Months Through 4 Years of Age Following Request From U.S. FDA


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that following a request from the U.S. Food and Drug Administration (FDA) the companies have initiated a rolling submission

Pfizer Announces New Chief Development Officerhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces New Chief Development Officer


Pfizer Inc. (NYSE: PFE) today announced that William Pao, M.D., Ph.D., will join the Company as Executive Vice President and Chief Development Officer effective March 21, 2022. Dr. Pao will be a

Waters Acquires Charge Detection Mass Spectrometry Technology to Broaden its Application in Cell and Gene Therapy: https://mms.businesswire.com/media/20191105005256/en/560437/5/Waters_logo_K.jpg
Waters Acquires Charge Detection Mass Spectrometry Technology to Broaden its Application in Cell and Gene Therapy


Waters Corporation (NYSE:WAT) today announced it has acquired the technology assets and intellectual property rights of Megadalton Solutions, Inc., an early-stage developer of Charge Detection Mass

European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancerhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer


Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) granted marketing authorization for LORVIQUA® (lorlatinib, available in the U.S. under the brand name LORBRENA®) as

Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatmenthttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Receives CHMP Positive Opinion for Novel COVID-19 Oral Treatment


Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional

Go365® by Humana Announces Winners of Fourth Annual National Step Challenge, Resulting in 7.2 Billion Steps Taken and One Million Meals Donated to Feeding America®: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Go365® by Humana Announces Winners of Fourth Annual National Step Challenge, Resulting in 7.2 Billion Steps Taken and One Million Meals Donated to Feeding America®


Today, leading health and well-being company, Humana Inc. (NYSE: HUM), announced the winners of its 2021 Go365 National Step Challenge – a health and wellness competition that focuses on improving

 Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Agehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
 Pfizer and BioNTech Initiate Study to Evaluate Omicron-Based COVID-19 Vaccine in Adults 18 to 55 Years of Age


Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a clinical study to evaluate the safety, tolerability and immunogenicity of an Omicron-based vaccine

Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time.: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Schedules Fourth Quarter and Full Year 2021 Earnings Release and Conference Call for February 10, 2022 at 4:30 p.m. Eastern Time.


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Thursday, February 10, 2022. Management will hold a

Agilent Announces the Innovative Seahorse XF Pro Analyzer: https://www.flatex.at/fileadmin/dateien_flatex/images/logos/logo-claim_flatex-at_positiv_rgb.png
Agilent Announces the Innovative Seahorse XF Pro Analyzer


Agilent Technologies Inc. (NYSE: A) today announced the release of the Agilent Seahorse XF Pro Analyzer, featuring new pharma-oriented workflow solutions incorporating advanced experimental design

U.S. Food and Drug Administration Expands Deployment of Waters Corporation Software to Support its Medical Products Testing Labs: https://mms.businesswire.com/media/20191105005256/en/560437/5/Waters_logo_K.jpg
U.S. Food and Drug Administration Expands Deployment of Waters Corporation Software to Support its Medical Products Testing Labs


Waters Corporation (NYSE: WAT) today announced the U.S. Food and Drug Administration’s (FDA) Office of Regulatory Affairs (ORA) has purchased Waters™ Empower™ Chromatography Data Software (CDS) and